A newly issued SEC–FDA memorandum of understanding formalizes information-sharing channels that will intensify dual oversight of pharma and biotech disclosures. The SEC will have enhanced access to FDA expertise when reviewing corporate disclosures, while the FDA will monitor how companies communicate regulatory status and commercial prospects to investors. For public companies, the practical impact is higher scrutiny of narrative risk factors, MD&A, and press releases tied to trial results and regulatory approvals, raising the bar for precision and documentation.